BiotechTube
IXALTIS

IXALTIS

Lyon, France· Est.
ixaltis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $40M

Overview

IXALTIS is a private, clinical-stage biotech developing therapies for urogenital diseases with high unmet medical need. Its strategy centers on in-licensing and repurposing previously developed clinical compounds, with its lead asset, Litoxetine (IXA-001), currently in Phase II for an unspecified urogenital indication. The company is backed by a specialized team, a world-class scientific advisory board, and has secured Series A financing from investor IXO Private Equity. Its model aims to de-risk and accelerate development by building on existing clinical data.

UrologyNephrologyUrogynecology

Technology Platform

Clinical-stage asset repurposing and development platform focused on genitourinary disorders.

Funding History

2
Total raised:$40M
Series B$25M
Series A$15M

Opportunities

The high unmet medical need in genitourinary disorders (e.g., overactive bladder, interstitial cystitis) presents a large and growing market.
IXALTIS's asset repurposing strategy offers a potentially faster, lower-risk development path to address these needs.
Positive Phase II data for Litoxetine could trigger partnership deals and significantly increase company valuation.

Risk Factors

The company faces significant clinical risk if its lead asset, Litoxetine, fails in Phase II trials.
As a pre-revenue private company, it is dependent on raising additional capital, which is contingent on positive data.
The competitive landscape for urogenital drugs is intense, with many novel mechanisms in development.

Competitive Landscape

IXALTIS competes in the genitourinary therapeutic area with large pharma (e.g., Astellas, Pfizer) and numerous biotechs developing novel therapies for OAB, IC/BPS, and other conditions. Its differentiation lies in repurposing compounds with known human safety profiles, aiming for a de-risked and expedited development pathway compared to novel molecular entities.

More companies in Small Molecule Drugs →More companies in France →